Navigation Links
Gerber Scientific to Hold Fiscal Year 2008 Fourth Quarter and Full Year Conference Call
Date:6/12/2008

SOUTH WINDSOR, Conn., June 12 /PRNewswire-FirstCall/ -- Gerber Scientific, Inc. (NYSE: GRB), a worldwide leader in integrated automation solutions, will hold a conference call with analysts and investors on Thursday, June 19, 2008, at 10:00 a.m. (Eastern Time) to discuss fiscal 2008 fourth quarter and full year financial results and provide a Company update. The Company will issue its earnings release for the fiscal 2008 fourth quarter and full year on June 19, 2008 before the market opens.

To participate, please dial the following number approximately 5 - 10 minutes prior to the scheduled starting time:

785-830-1923 (Access Code: 3858448)

The conference call will also be broadcast live over the internet and can be accessed by logging on to http://www.gerberscientific.com approximately 5 - 10 minutes prior to the call.

If you are unable to participate in the live webcast, it will be archived on the company's website for 30 days. Minimum requirements to listen to the broadcast: The Windows Media Player software, downloadable for free from http://www.microsoft.com/windows/windowsmedia/mp10/default.aspx and at least a 28.8 Kbps connection to the Internet.

About Gerber Scientific, Inc.

Gerber Scientific, Inc. (http://www.gerberscientific.com) is a leading international supplier of sophisticated automated manufacturing systems for sign making and specialty graphics, apparel and flexible materials, ophthalmic lens processing, and print and packaging industries. Headquartered in South Windsor, Connecticut, the company operates through four businesses: Gerber Scientific Products and Spandex Ltd., Gerber Technology, and Gerber Coburn.

Forward-looking Statements:

In addition to the historical information contained herein, there are matters discussed that are considered to be "forward-looking statements." These forward-looking statements involve risks and uncertainties, including, but not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, markets, products, and services, that could significantly affect results in the future. For a discussion of other risk factors relating to the Company's business, see the Company's Annual Report on Form 10-K for the year ended April 30, 2007, as filed with the Securities and Exchange Commission. The forward-looking statements contained in this release are made as of the date of this release, and the Company expressly disclaims any obligation to update or revise any forward-looking statements contained in this release, except as required by law.


'/>"/>
SOURCE Gerber Scientific, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jobson Medical Information LLC Acquires Gerber Communications and Practice Advancement Associates
2. Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference
3. Paramount Farms Establishes Scientific Advisory Board to Advance Understanding of the Health Benefits of Pistachios
4. ATS Medical Products Prominently Featured in International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Scientific Presentations
5. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
6. Milestone Scientific Expands U.S. and Canadian Distribution Network With Addition of Patterson Dental Supply
7. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
8. Milestone Scientific Expands Global Distribution Network
9. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
10. The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
11. Kewaunee Scientific Corporation Increases Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Plano, TX (PRWEB) , ... April 26, 2017 ... ... to confer the distinction of Customer Excellence upon National Registry of Emergency ... , “Customer Engagement drives Financial Performance,” said Dr. Jan G. West, Ph.D. ...
(Date:4/26/2017)... ... , ... RawTrition now brings you BioEnergy which is a powder capsule whole ... , RawTrition is taking nutrients to the next level! The superfoods in RawTrition's ... form (unlike the synthetically made options that are on the market). , Founder of ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 product ... for education and business. , Mirroring360 Pro enables educators, business professionals and individuals ...
(Date:4/25/2017)... Amherst, NY (PRWEB) , ... April 25, 2017 , ... ... much stress at work can also decrease overall productivity and performance in the workplace. ... their employees. , During the last few weeks of April, Clearview Resolution Services will ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Urology, Uro/Gyn and Gynecology markets with innovative and ... joined the Company as Senior Vice President, Marketing ... Mr. Keswani will report directly to Darin ... organization is delighted that Ash has joined the ...
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: